ScripBristol Myers Squibb is following Merck & Co. and Pfizer by buying into the bispecific PD-L1xVEGF-targeting mechanism for cancer, announcing on June 2 that it will pay $1.5bn up front to BioNTech
ScripPfizer has thrust into the global race for a best-in-class bispecific antibody that inhibits both programmed cell death protein 1/ligand 1 (PD-1/L1) and vascular endothelial growth factor (VEGF) as it
ScripWhile President Trump’s efforts to downsize the US Food and Drug Administration and plans to impose tariffs are currently spooking biopharma investors, some companies were able to defy the gloomy sent
ScripJohnson & Johnson unveiled its second atopic dermatitis-focused deal this month on 28 May, paying $1.25bn in cash to acquire a subsidiary of Numab Therapeutics AG that houses a Phase II-ready bispe